Biotech Stock News (SYN) (CNAT)

Synthetic Biologics (NASDAQ:SYN) On February 3, 2016 shares of Synthetic Biologics fell by 14% after the company announced an update on the phase 2 clinical trial treating patients with Relapsing-Remitting Multiple Sclerosis — RRMS. The company’s drug used to treat these patients with RRMS is known as Trimesta. Both the clinical and MRI results of … Read more

Biotech Stock News (RPTP) (AERI) (CANF)

Raptor Pharmaceuticals (NASDAQ:RPTP) On Monday September 14, 2015 shares of Raptor Pharmaceuticals ended the day down 38% after the company announced that it had failed a phase 2b liver study in children with NASH — non-alcoholic steatohepatitis. The phase 2b trial enrolled up to 169 children with NASH between the ages of eight and seventeen. … Read more